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CD23, the low affinity IgE receptor found on B 
lymphocytes and other cells, contains a C-terminal 
lectin-like domain that resembles C-type 
carbohydrate-recognition  domains  (CRDs)  found 
in many glycan-binding receptors. In most 
mammalian species, the CD23 residues required to 
form a sugar-binding site are present, although 
binding of CD23 to IgE does not involve sugars. 
Solid-phase binding competition assays, 
glycoprotein blotting experiments and glycan array 
analysis employing the lectin-like domains of cow 
and mouse CD23 demonstrate that they bind to 
mannose,  N-acetylglucosamine,  glucose,  and 
fucose and to glycoproteins that bear these sugars 
in  nonreducing  terminal  positions.  Crystal 
structures of the cow CRD in the presence of α- 
methyl mannoside and GlcNAcβ1-2Man reveal that 
a range of oligosaccharide ligands can be 
accommodated in an open binding site in which 
most interactions are with a single terminal sugar 
residue. Although mouse CD23 shows a pattern of 
monosaccharide and glycoprotein binding similar 
to cow CD23, the binding is weaker. In contrast, no 
sugar binding was observed in similar experiments 
with human CD23. The absence of sugar-binding 
activity correlates with accumulation of mutations 
in the CD23 gene in the primate lineage leading to 
humans, resulting in loss of key sugar-binding 
residues. These results are consistent with a role for 
CD23 in many species as a receptor for potentially 
pathogenic micro-organisms as well as IgE. 
However, the ability of CD23 to bind several 
different ligands varies between species, suggesting 
that it has distinct functions in different organisms. 
 
 
CD23, also designated FcεRII and CLEC4J, is a 
cell-surface receptor for the Fc domain of 
immunoglobulin E, which regulates IgE synthesis 
(1). In addition to IgE, several other endogenous 
ligands  have  been  proposed  to  bind  to  human 
CD23, including CD21, major histocompatibility 
locus class II receptors and integrins αMβ2 (CD11b- 
CD18), αXβ2 (CD11c-CD18), αVβ3 (vitronectin 
receptor)  and  αVβ5   (2-4).  These  ligands  interact 
with the extracellular, C-terminal portion of the 
receptor polypeptide. A portion of the extracellular 
domain can be released from the cell surface by 
proteolysis and can act on target cells by binding to 
ligands   such   as   CD21   (2).   The   N-terminal 
cytoplasmic domain of the intact, membrane-bound 
form of CD23 also has multiple binding partners. In 
humans and mice, two isoforms of CD23, which 
result from differential splicing, have different N- 
terminal sequences (5). The presence of these 
different sequences correlates with the ability to 
mediate internalization of bound ligands, by 
endocytosis or phagocytosis, and to activate 
intracellular signaling pathways (4-6). One splice 
variant, designated CD23a, is expressed primarily 
on B lymphocytes, while variant CD23b is more 
broadly  expressed  on  hematopoietic  cells, 
including  B  and  T  lymphocytes, 
polymorphonuclear leukocytes, and follicular 
dendritic cells, as well as intestinal epithelial cells 
and bone marrow stromal cells. 
The extracellular portion of CD23 consists of a 
C-terminal  C-type lectin-like domain attached to 
the membrane by an extended neck region (1). The 
lectin-like domain is related to the C-type 
carbohydrate-recognition  domains (CRDs3) found 
in   many   mammalian   glycan-binding   receptors 
(7,8).  The  neck  region  has  been  proposed  to 
mediate formation of receptor trimers and is also 
implicated in binding to major histocompatibility 
locus class (MHC) II receptors (3,9). IgE and 
integrin binding have been mapped to different 
surfaces of the C-type lectin-like domain (10,11), 
while binding of CD21 to a C-terminal extension is 
observed for human CD23, an interaction not 
conserved in mouse CD23 (12). Crystal structures 
of the C-terminal portion of human CD23 in 
complex with the Cε3 and Cε4 domains of IgE 
suggest a possible mode of interaction of the 
receptor with its immunoglobulin ligand, in which 
CD23 lectin-like domains bind to the Cε3 domains 
of the IgE dimer on the outside of a cavity formed 
by the Cε3 and Cε4 domains (10,13). Binding to 
IgE is independent of the N-linked glycans attached 
to domain Cε3, which point into the cavity. 
The C-type lectin-like domain of human CD23 
resembles a sugar-binding domain, although there 
is conflicting evidence regarding the role of sugars 
in binding to different ligands. Recent studies with 
mouse CD23 show that it binds α-mannans and β- 
glucans from fungal cell walls, suggesting that 
CD23 from at least some species does have sugar- 
binding activity (14). Binding of sugars to C-type 
CRDs results from a common set of interactions 
between two sugar hydroxyl groups in a pyranose 





acid side chains on the protein (7,8). Many C-type 
lectin-like domains lack these conserved residues 
and interact with non-carbohydrate ligands, usually 
in  a  Ca2+-independent  manner  (7).  Examples  of 
such structurally and functionally distinct proteins 
include a family of natural killer cell receptors that 
bind  major  histocompatibility-related   molecules 
and a receptor for oxidized low-density lipoprotein. 
Sequence comparisons indicate that these proteins 
lack  the  conserved  Ca2+-  and  sugar-binding 
residues and for the most part they form a distinct 
evolutionary   group   separate   from   the   various 
groups of sugar-binding receptors. In contrast, the 
residues needed for sugar binding are conserved in 
mouse CD23 and sequencing of the FCER2 gene 
from cow confirms that these residues are also 
present in cow CD23.4 
Conservation of the sugar-binding residues 
prompted   a   re-evaluation   of   sugar-binding   of 
CD23. The results reported here demonstrate that 
CD23 from both cows and mice does bind to sugars 
in a Ca2+-dependent manner, but that this activity 




Sugar-binding activity of cow CD23 
The overall organization of CD23 proteins is 
summarized in Figure 1A. An α-helical coiled-coil 
domain characterized by the presence of a heptad- 
repeat pattern of aliphatic hydrophobic amino acids 
in the stalk domain (Figure 1B) mediates trimer 
formation. The globular C-terminal lectin-like 
domain is characterized by the presence of 
conserved cysteine residues that form disulfide 
bonds (Figure 1B). The pattern of disulfide bonds 
is analogous to the arrangement of other C-type 
CRDs (10,13,15,16). The alignment also reveals 
conservation of Ca2+  ligands in the mouse and cow 
proteins, but some of these residues are absent in 
the human protein. 
Following protocols that have been used for 
purification of other C-type CRDs, a fragment of 
Bos taurus  CD23 encompassing residues Ala157 
to Cys290, corresponding to the globular domain, 
was expressed in Escherichia coli. This segment of 
cow CD23 corresponds to the extensively 
characterized fragment of human CD23 that is 
produced by the Der P 1 protease from house mites, 
although cow CD23 lacks the C-terminal extension 
present  in  human  CD23  (Fig.  1B)  (10).  Folded 
protein was obtained by dissolving inclusion bodies 
in guanidine and renaturation by dialysis in the 
presence of Ca2+. Sugar binding was tested by 
chromatography on a series of resins bearing 
immobilized monosaccharides, including mannose, 
GlcNAc, fucose, and galactose. Bound protein was 
eluted with EDTA. Binding was observed for the 
mannose and fucose resins (data for mannose 
shown; Fig. 1C). A significant amount of protein 
leaches off the column in the Ca2+-containing wash 
buffer that precedes the EDTA elution, indicating 
that binding is not as tight as for some CRDs, but 
the result indicates that cow CD23 does display 
Ca2+-dependent  sugar-specific  binding.  To 
facilitate further analysis of the sugar-binding 
activity, an additional version of the CRD was 
expressed with a biotinylation sequence appended 
at the C-terminal end (Fig. 1D). 
 
Sugar-binding specificity of cow CD23 
The C-terminal biotinylation sequence was used 
to immobilize the CRD from cow CD23 in 
streptavidin-coated wells, which were probed using 
horseradish peroxidase as a reporter ligand. The 
mannose-terminated  oligosaccharides  on 
horseradish peroxidase make it a convenient ligand 
for mannose-binding  CRDs that can be detected 
with a chromogenic substrate (17). Binding 
competition  assays  were  used  to  compare  the 
affinity of the CRD for a range of monosaccharides 
(Fig. 2A). The three monosaccharides with highest 
affinity are mannose, fucose, and GlcNAc, which is 
typical for many C-type CRDs that bind sugars with 
equatorial 3- and 4-OH groups (18). Several 
disaccharides were also tested, to see if there is a 
strong preference for a particular linkage, but the 
affinities differ by at most 2-fold. However, the 
affinity for a Man9GlcNAc2  oligosaccharide was 
substantially enhanced (Fig. 2B). 
The pH dependence of binding was also tested, 
demonstrating that the CRD releases ligand when 
the pH falls below 6 (Fig. 2C). This type of pH 
dependence is observed in recycling endocytic 
receptors that release their ligands at endosomal pH 
(19). The N-terminal sequence of the splice variant 
of CD23 shown in Figure 1A contains the motif 
YSEF, which is analogous to the sequences YSEI 
in human CD23 and YSGY in mouse CD23. This 
motif represents a binding site for clathrin adapter 
protein 2, which is responsible for endocytosis of 





Thus, the sequence of the cytoplasmic domain, as 
well as the pH-dependent binding of sugar ligands, 
are consistent with the suggestion that cow CD23 
could mediate internalization of ligands based on a 
sugar-dependent recognition mechanism. 
The  ligand-binding  specificity  of  cow  CD23 
was examined further by probing a glycan array 
with biotinylated CRD in complex with 
fluorescently labeled streptavidin (Fig. 3A). The 
results reveal binding to a wide range of glycan 
ligands, with a relatively broad and continuous 
distribution of intensities on the array, rather than 
highly selective binding to a single small class of 
ligands. However, some patterns can be observed 
(Fig. 3B). Most of the binding observed can be 
accounted for by the presence of one of three 
different epitopes. Many of the glycans that bind 
CD23   bear  the  disaccharide   GlcNAcβ1-2Man, 
either exposed at a non-reducing terminus or with 
galactose residue appended to the 3 position of the 
GlcNAc residue. A second common epitope is a 
Fucα1-2Gal disaccharide and several oligo- 
mannose structures are also bound. 
While these patterns suggest some degree of 
specificity beyond monosaccharide binding, it is 
important to note that other glycans that contain 
these structures do not bind as well and the 
differences in affinity are relatively small. Thus, the 
binding may well reflect the similar affinities 
observed for mannose, GlcNAc and fucose methyl 
glycosides, with different intensities of signals 
reflecting  at  least  in  part  accessibility  and 
abundance of these terminal residues. 
Similar observations were also made when 
glycoproteins were tested as ligands. Glycoproteins 
blotted onto nitrocellulose membranes were probed 
with CRD complexed with alkaline-phosphatase 
conjugated avidin complex (Fig. 4). The results in 
Figure 4A demonstrate that the main serum ligand 
for CD23 appears to be IgG, which presumably 
reflects the presence of some exposed terminal 
GlcNAcβ1-2Man groups. The results are consistent 
with binding to oligomannose structures on RNase 
B (Fig. 4B). Exposure of terminal GlcNAcβ1-2Man 
groups on α1  acid glycoprotein dramatically 
enhances binding, although the natural protein is a 
poor ligand. 
 
Structural basis for sugar binding to cow CD23 
The mechanism of sugar binding to cow CD23 
was examined by x-ray crystallography. Crystals of 
the CRD from cow CD23 were obtained under 
conditions that allow binding of sugar ligands: in 
the presence of 5 mM Ca2+. Crystals obtained in the 
presence of α-methyl mannoside and GlcNAcβ1- 
2Man diffracted to 1.00 and 1.20 Å, respectively 
and crystals with GlcNAc2Man3  oligosaccharide 
diffracted to 2.7 Å. The structure of the α-methyl 
mannoside complex was solved by molecular 
replacement, using the human CD23 structure (20) 
as the search model; this complex was then used to 
solve the other structures. The cow CD23 structure 
shows a typical C-type CRD fold (Fig. 5A) and the 
bound sugar ligands are well defined (Fig. 5B-E). 
The structure of cow CD23 confirms the presence 
of the four disulfide bonds predicted from the 
alignment with other C-type CRDs and also shows 
that there are two bound Ca2+, representing the 
conserved Ca2+  found at sugar-binding sites in C- 
type CRDs and the adjacent accessory site. The 
bound Ca2+ (Fig. 5F,G) are ligated by the predicted 
residues that are highlighted in Figure 1A. Several 
different crystal forms of the CRD from human 
CD23 have previously been characterized, two of 
which  were  obtained  in  the  presence  of  Ca2+ 
(13,20).  These  structures  reveal  the  presence  of 
only a single Ca2+, corresponding to the conserved 
principal site. The absence of the accessory Ca2+ 
correlates with changes at two of the positions that 
correspond to ligands for this Ca2+ in cow CD23. 
Crystals obtained in the presence of the simple 
sugar ligands α-methyl mannoside and GlcNAcβ1- 
2Man showed that binding of mannose at the 
primary binding site results from coordination and 
hydrogen bonds with the 3- and 4-OH groups in the 
arrangement  typically  seen in C-type CRDs that 
bind mannose and related sugars (Fig. 5F,H). The 
GlcNAc residue in the GlcNAcβ1-2Man 
disaccharide makes only a few additional contacts 
with the surface of the CRD (Fig. 5I). The surface 
near to the primary binding site lacks obvious 
protrusions, so it is hard to define a secondary or 
extended binding site that would favor particular 
oligosaccharide ligands or occlude others. These 
observations are consistent with the relatively broad 
range of ligands bound in the glycan array 
experiment. 
When comparing cow CD23 and human CD23, 
the largest conformational differences are in two 
regions of the CRD that correspond to loops 1 and 
4 (Fig. 6). The conformational differences are 





previous work, it has been noted that these loops 
differ between human CD23 crystals obtained in 
the presence or absence of Ca2+  (13). Ca2+  binding 
in the primary site induces a 30-fold increase in 
affinity for IgE. The differences are seen both in the 
CRD structures and also in the complexes of human 
CD23 with IgE (Fig. 6). The Ca2+-bound 
conformations of human and cow CD23 differ from 
each  other.  In  cow  CD23,  loops  1  and  4  are 
involved in binding both the conserved and the 
accessory Ca2+ site, while the latter site is missing 
in the human structure. Pro252 of cow CD23 is in 
the cis configuration typically found in C-type 
CRDs  with  bound  Ca2+.  Although  the 
corresponding residue in human CD23, Pro250, is 
also in cis configuration, the conformation of the 
remainder of this loop is different from the cow 
structure and there are significant differences in the 
Ca2+  ligands.  In cow CD23, the side chains of 
Asn253 and Glu259 bind the conserved Ca2+, and 
the side chain of Asp254 binds the accessory Ca2+ 
that is absent in the human protein. The residue 
corresponding to Asp254 in cow CD23 is Ser252, 
which does not interact with Ca2+, and Glu257 in 
human CD23, corresponding to Glu259 in cow 
CD23, is a Ca2+ ligand in some of the crystal forms 
but not others. 
The surface of human CD23 that interacts with 
domains Cε3 and Cε4 of IgE is largely conserved 
in the cow protein, specifically residues Trp186, 
Ile187, Gln188, Arg190 and Tyr191 in the first 
helix, and also residues Arg226 and Phe274. 
However, other interactions between human CD23 
and IgE mediated by loops 1 and 4 (Fig. 6) could 
not occur with the cow protein, as these loops differ 
in sequence and conformation between human and 
cow CD23. Also, the surface of human CD23 that 
interacts with domain Cε2 of IgE does not seem to 
be conserved: the fold is similar but not the 
sequence. 
An additional crystal form of the CRD from cow 
CD23 was obtained in complex with a bi-antennary 
glycan  terminating  in  two  GlcNAcβ1-2Man 
groups.  The  oligosaccharide  bridges  between 
CRDs related by a crystallographic twofold 
symmetry  axis,  so  the  electron  density  for  the 
sugars represents an average of two possible 
orientations (Fig. 7). In each binding site, the 
terminal GlcNAcβ1-2Man residues occupy 
approximately the same positions as in the crystal 
with   GlcNAcβ1-2Man   disaccharide   (Fig.   5H). 
Analysis using CARP and GlycoMapsDB shows 
that the observed torsion angles in the 
oligosaccharide are similar to other experimentally 
observed structures and to the favored 
conformations predicted from energy calculations 
(21,22). Thus, it does not seem that the crystal 
packing distorts the oligosaccharide structure. The 
relative orientation of the two CRDs bound to a 
single oligosaccharide suggests a way in which 
binding to oligosaccharides could crosslink CRDs 
in two adjacent CD23 molecules on the surface of a 
cell, which represents a potential mechanism for 
initiating signaling (Fig. 7). 
 
Expression of CD23 on bovine B cells 
A previous screen of antibodies to human 
proteins against bovine tissues identified a 
commercially  available  monoclonal  antibody 
raised against human CD23 that cross reacts with 
cow CD23 (23). The ability of the antibody to bind 
cow CD23 was verified by western blotting. Flow 
cytometry of peripheral blood mononuclear cells 
isolated from bovine blood revealed expression of 
CD21+  B cells (Fig. 8), consistent with the pattern 
of human and mouse CD23 expression on mature 
circulating B cells. 
 
Mouse CD23 displays similar but distinct sugar- 
binding activity 
The amino acid residues that form the sugar- 
binding site in cow CD23 are conserved in mouse 
CD23 (Fig. 1B). Demonstration that cow CD23 has 
sugar-binding activity, as well as recent studies on 
binding of mouse CD23 to fungal cell wall 
polysaccharides (14), suggested that mouse CD23 
would also bind sugars. A CRD fragment of mouse 
CD23, expressed with a C-terminal biotin tag in the 
same way as the cow protein, bound only weakly to 
the mannose-Sepharose resin, although retardation 
relative to other proteins was evident (Fig. 9A). 
Increased affinity was achieved by forming a 
tetrameric complex with streptavidin, which bound 
more tightly to the resin in the presence of Ca2+ and 
was then eluted with EDTA, confirming that mouse 
CD23 binds sugars in a Ca2+-dependent manner, 
although with lower affinity than cow CD23 (Fig. 
9B). 
Sugar binding was further characterized by 
applying  biotin-tagged  mouse  CD23  to 
streptavidin-coated assay plates and probing these 





competition assays with monosaccharides revealed 
binding to a similar range of sugars as for cow 
CD23, although the KI values for mouse CD23 are 
consistently higher, reflecting weaker binding to all 
of the sugars. Blotting experiments with the mouse 
CRD in complex with alkaline phosphatase- 
conjugated streptavidin also showed binding to a 
similar selection of glycoproteins as for cow CD23, 
including RNase B, with high mannose 
oligosaccharides, and asialo, agalacto-α1-acid 
glycoprotein (Fig. 11). Attempts were also made to 
probe the glycan array with fluorescently labeled 
streptavidin-CRD  complex.  Because  of  the 
relatively weaker binding affinity, higher 
concentrations of complex were required to obtain 
signals. However, there were high background 
signals covering significant areas of the array 
surface, possibly reflecting protein aggregation, 
which resulted in positive signals for a wide range 
of oligosaccharides and the results of several 
independent experiments did not correlate well. 
Thus, the arrays did not provide any further insights 
into the binding specificity of the mouse CD23. 
 
Absence of equivalent sugar-binding activity in 
human CD23 
Similar  fragments  corresponding  to  the  CRD 
from human CD23 failed to show any binding 
activity by affinity chromatography, even when 
biotin-tagged CRDs were complexed with 
streptavidin   to  increase   the  affinity   (data  not 
shown). These results correlate with the absence of 
one of the key Ca2+-ligating residues at the primary 
sugar-binding site (Fig. 1A). The importance of 
residue Asn253 is shown in the crystal structure of 
cow CD23, which confirms its role as both a 
coordination ligand for Ca2+  and a hydrogen bond 
donor that interacts with one of the sugar hydroxyl 
groups. The presence of a threonine residue at this 
position in human CD23 is thus consistent with the 
absence  of  detectable  sugar-binding  activity 
(13,20). 
Phylogenetic analysis of the sequences of CD23 
orthologs  in a wide variety  of mammals  reveals 
that, although the residues that form the sugar- 
binding site in cow CD23 are present in most 
mammalian species, one or more of these residues 
are absent in many primate species (Fig. 12). In 
most of these cases, there are multiple mutations 
that would be expected to disrupt the Ca2+- and 
sugar-binding sites, although the specific mutations 
vary between different groups of primates and even 
between species within one group. The pattern of 
amino acid substitutions suggests that a mutation 
that resulted in loss of sugar-binding activity 
occurred in the progenitor to the branch of primates 
that includes the old and new world monkeys and 
the apes, but is separate from the lineage leading to 
tarsiers. Once sugar-binding activity was lost, 
selective pressure to retain other residues that form 
the Ca2+- and sugar-binding sites was absent and 
additional mutations in key residues occurred. 
 
Discussion 
Demonstration that cow and mouse CD23 bind 
to sugars highlights a new class of ligands for this 
multifunctional receptor. Binding by the Ca2+- 
coordination mechanism common to most C-type 
CRDs involves a distinct face of the CRD compared 
to other ligands that interact with this domain, such 
as IgE and integrins. The distribution of these 
binding surfaces is summarized in Figure 13. The 
fact that many of the interactions of CD23, such as 
the binding of IgE and binding of short consensus 
repeat domains 1 and 2 of CD21, are sugar- 
independent (24), is consistent with the distinct 
locations of the sugar-binding site and the sites on 
the surface of CD23 that bind these other ligands. 
Spatial separation of the binding sites for sugar and 
for CD21 suggests that the effect of CD21 
glycosylation on binding to CD23 may be indirect 
rather than through the sugar-binding site (25). If 
the cow protein bound to IgE in the manner found 
in the human CD23, conformational changes would 
have to occur in loops 1 and 4, or perhaps in the 
IgE, that would potentially alter the sugar-binding 
site. Indeed, a structure of human CD23 with Ca2+ 
(13) shows changes in these loops that result in 
direct contacts with IgE. 
The sugar-binding activity of cow CD23 is 
consistent with the presence of all of the ligands for 
the conserved Ca2+ required for interaction with 
sugars. One feature of this binding site is the Glu- 
Pro-Asn motif, which wraps around the Ca2+ and is 
associated with binding to sugars with equatorial 3- 
and 4-OH groups, such as mannose, GlcNAc, and 
glucose. The relatively open binding site allows 
interaction with these monosaccharides in multiple 
contexts, although some type of oligosaccharide 
ligands appear to be favored as a result of a small 






Mouse CD23 binds to a similar spectrum of 
ligands, but with distinctly weaker affinity. The 
reasons for this weaker affinity are not completely 
clear. The solid phase binding competition assays 
are  conducted   under  conditions   in  which   the 
reporter ligand, horseradish peroxidase, is far below 
saturation, so the KI values measured for the 
monosaccharides correspond closely to their KDs. 
Thus, the results suggest fundamentally weaker 
binding  at  the  primary  monosaccharide  binding 
site. This difference is seen in spite of the fact that 
the coordination ligands for the primary Ca2+ are 
completely conserved and no other side chains 
within 4 Å of the monosaccharide residue in the 
primary binding site differ between cow and mouse 
CD23. The swap of aspartic acid for asparagine at 
position 254 and the reverse swap at position 260 
would also be expected to preserve the secondary 
Ca2+ binding site. It is possible that changes further 
from the sugar-binding site result in conformational 
changes affecting the positions of conserved 
residues   in   the   primary   binding   site.   In   the 
secondary binding site, Ser277, which forms a 
hydrogen bond with O6 of GlcNAc, is found in cow 
and mouse, but not human, CD23 and Met263, 
which contacts C4 of GlcNAc, is conserved in cow, 
mouse and human CD23. However, Leu265 in cow 
CD23, which contacts the carbonyl oxygen on the 
GlcNAc acetamido group, is replaced by Arg in 
mouse and human CD23, and it is not clear whether 
an equivalent  contact  would  be made.  The 
difference between cow and mouse CD23 at this 
position might further reduce the affinity for 
oligosaccharide ligands, in line with the negative 
glycan array results. 
In  early  studies,  Ca2+-dependent  binding  of 
mouse CD23 to monosaccharide-derivatized beads 
was reported based on an indirect assay, but no 
quantitative analysis was undertaken (24). The 
monosaccharide-binding characteristics of mouse 
CD23 reported in the present work are consistent 
with more recent results suggesting that mouse 
CD23 interacts with α-mannans and β-glucans from 
fungi (14). The α-mannan from Candida albicans 
and other yeasts are decorated with terminal 1-2 
linked  sugars  that  have  exposed  3-  and  4-OH 
groups which would be able to interact with the 
binding site in CD23, consistent with the observed 
binding to Candida albicans cells as well as to the 
α-mannan from Saccharomyces cerevisiae (26). In 
the  case  of  Aspergillus  fumigatus,  the  wall  β- 
glucans contain appended mannose and GlcNAc 
residues that would be potential ligands (27). 
However, the fact that bacterial curdlan can be used 
to mimic the effects of the fungus suggests that 
glucose residues also can mediate binding to CD23 
(14,28). Although the main chain β1-3 linkages 
would block the 3-OH groups on glucose and 
prevent  binding,  glucose  residues  at  the 
nonreducing termini of chains would be able to 
interact  with  CD23.  Previous  studies  have 
suggested that human CD23 mediates pathogen 
recognition indirectly by forming complexes with 
IgE bound to mycobacteria or leishmania parasites 
(29,30), but the results presented here and in the 
recent study of binding to fungi are consistent with 
a direct mechanism  for mouse CD23 interacting 
with sugars on the surfaces of micro-organisms. In 
cows, there might be a particular need for such 
direct recognition of micro-organisms. As 
ruminants, cows may have high levels of non- 
pathogenic bacteria and fungi in the intestinal tract 
and appropriate recognition may be necessary to 
maintain T cell anergy on the intestinal surfaces. 
Absence of detectable sugar-binding activity for 
human CD23 might be expected, because one of the 
ligands at the conserved Ca2+  site is absent. Earlier 
results suggesting galactose-mediated binding of 
human CD23 to various glycoproteins are difficult 
to interpret, because the CD23 was not purified. It 
is therefore not clear if CD23 itself was responsible 
for the interactions observed (31,32). It is important 
to note that although the GluProAsn sequence in the 
C-type CRDs in pulmonary surfactant protein A 
from  various  species  is  changed  to  either 
GluProAla or GluProArg, these CRDs still bind 
sugars, albeit with relatively weak affinity (33). 
However, it is clear from the results with mouse 
CD23 that factors in addition to the residues 
immediately around the conserved Ca2+ site 
contribute to forming a functional sugar-binding 
site, so a combination of changes can further reduce 
binding to the point where it is difficult or 
impossible to detect. It is striking that multiple 
additional changes at the Ca2+-binding sites occur 
in many of the primate species, which strongly 
suggests that the sugar-binding activity is not 
selected for in this evolutionary branch of the 
mammals. 
Many of the glycan-binding receptors that have 
C-type CRDs are found on myeloid cells. The 





somewhat exceptional. The only other glycan- 
binding receptor with a C-type CRD found on B 
cells is prolectin (34). Comparison of the C-type 
CRDs  reveals  that  the  CRD  of  CD23  is  more 
similar in sequence to prolectin than it is to any 
other CRD (8). In cows, the prolectin and CD23 
genes are both on chromosome 7 and in humans the 
prolectin and CD23 genes are both located on 
chromosome 19. The prolectin gene is absent from 
mice and other rodents, but is present in humans 
and thus could possibly assume functions on B cells 
that human CD23 does not perform because of the 
loss of sugar-binding activity. 
A key feature of the sugar-binding activity is 
sensitivity to pH. Loss of sugar-binding activity 
would occur in the pH range found in endosomal 
compartments  and  is  consistent  with  a  role  for 
CD23 as a recycling endocytic receptor, which 
would bind ligands at the cell surface and release 
them following internalization, so that the receptor 
can return to the cell surface while the ligand is 
routed toward lysosomes for degradation. This 
function would depend on the presence of the 
YXXL adapter-protein binding site in the 
cytoplasmic domain, which allows interaction with 
clathrin and is found in one of the two main splice 
variants of CD23 (5). The fact that this activity is 
present in CD23 expressed in some cells but not in 
others is consistent with the idea that CD23 plays 
multiple, distinct roles in different circumstances. 
 
Experimental procedures 
Cloning of expression constructs 
A spleen cDNA library from Bos taurus was 
obtained  from  AMS  Biotechnology  (Abingdon, 
UK)  and  a  mouse  spleen  cDNA  library  was 
obtained from Takara Bio Europe (Saint-Germain- 
en-Laye, France). PCR reactions were conducted 
with Advantage 2 DNA polymerase (Takara). A 
preliminary heating step for 2 min at 95 ºC was 
followed by 40 cycles of 30 s denaturation at 95 ºC 
followed by 2 min renaturation and elongation at 65 
ºC. Fragments were isolated by agarose gel 
electrophoresis and either used for a second round 
of amplification or were cloned into vector pCRII 
Topo using a TOPO cloning kit from Invitrogen 
(Paisley, UK). PCR primers used to amplify cow 
and mouse cDNAs, summarized in Figures S2 and 
S3,  were  purchased  from  Invitrogen.  For 
attachment of biotin tags, the 3' primer included a 
sequence encoding the biotinylation sequence Leu- 
AsnAspIlePheGluAlaGlnLysIleGluTrpHisGlu 
appended  to  the  C-terminus  of  the  protein.  The 
sequence of a cDNA used for expression of the cow 
CRD   without   a   biotin   tag,   synthesized   by 
Invitrogen, is given in Figure S4. 
 
Protein expression 
All cloned fragments were inserted into 
expression vector pT5T (35) in Escherichia coli 
strain BL21(DE3) and grown in Luria-Bertani 
medium in the presence of 50 µg/ml ampicillin. For 
proteins with biotin tags, the bacteria also contained 
plasmid pBirA, which encodes biotin ligase (36), 
and cells were grown in the presence of both 50 
µg/ml ampicillin and 50 µg/ml chloramphenicol. 
Overnight cultures (200 ml) grown at 25 ºC were 
used to inoculate 6 l of medium at 37 ºC. Protein 
expression was induced with 100 µg/ml isopropyl- 
β-D-thiogalactoside  when the OD550   reached 0.7. 
For proteins with biotin tags, biotin was also added 
to a concentration of 12.5 µg/ml at the time of 
induction. After a further 2.5 h at 37 ºC, cells were 
harvested by centrifugation. 
Inclusion  bodies  were  isolated  by  extensive 
sonication in 200 ml of 10 mM Tris-Cl, pH 7.8, 
followed by centrifugation at 15,000 x g for 15 min. 
The insoluble protein was dissolved in 100 ml of 6 
M guanidine HCl, 100 mM Tris-Cl, pH 7.0 by 
homogenization.   Fresh   2-mercaptoethanol   was 
added to a final concentration of 0.01% and 
incubated at 4 ºC for 30 min followed by 
centrifugation at 100,000 x g for 30 min. For 
renaturation of the cow CRD, the supernatant was 
dialyzed against 3 changes of 4 l of 0.5 M NaCl, 25 
mM Tris-Cl, pH 7.8, 25 mM CaCl2. The guanidine- 
solubilized mouse CRD was diluted into 400 ml of 
buffer before dialysis. After dialysis, insoluble 
protein was removed by centrifugation at 50,000 x 
g for 30 min. 
Mannose-Sepharose affinity resin was prepared 
by divinyl sulfone  coupling  (37). Renatured 
proteins  were  applied  to  10-ml  columns,  which 
were washed with 12 ml of 150 mM NaCl, 25 mM 
Tris-Cl, pH 7.8, 25 mM CaCl2  and eluted with 15 
1-ml aliquots of 150 mM NaCl, 25 mM Tris-Cl, pH 
7.8, 2.5 mM EDTA. Fractions containing protein 
were identified by analyzing aliquots by SDS- 
polyacrylamide gel electrophoresis. 
 





Biotin-tagged  proteins  were  incubated 
overnight at 4 ºC with fluorescently labeled 
streptavidin (Invitrogen) or streptavidin-alkaline 
phosphatase  conjugate  (Sigma  Chemical 
Company) at a ratio of approximately 2 moles of 
CRD to 1 mole of streptavidin monomer: 200 µg/ml 
of CRD and 100 µg/ml streptavidin. Complexes of 
cow CRD were isolated by gel filtration on a 
Superdex S200 column, 1 x 30 cm, eluted at 0.5 
ml/min with 100 mM NaCl, 10 mM Tris-Cl, pH 7.8, 
2.5 mM EDTA. Complexes of mouse protein were 
re-purified  on  1-ml  columns  of  mannose- 
Sepharose, which were washed with 1 ml of 150 
mM NaCl, 25 mM Tris-Cl, pH 7.8, 25 mM CaCl2 
and  eluted  with  5  0.25-ml  aliquots  of  150  mM 
NaCl, 25 mM Tris-Cl, pH 7.8, 2.5 mM EDTA. 
 
Solid phase binding assays 
Biotin-tagged  proteins,  diluted  to  a 
concentration of approximately 10 µg/ml in binding 
buffer (150 mM NaCl, 25 mM Tris-Cl, pH 7.8, 2.5 
mM CaCl2) containing 0.1% bovine serum albumin 
(Cohen Fraction V, Sigma Chemical Company), 
were applied to streptavidin-coated 96-well assay 
plates  (Pierce  Chemical  Company).  After 
incubation overnight at 4 ºC with 100 µl of this 
coating solution, the wells were washed 3 times 
with binding buffer. Competing sugars were added 
to  individual  wells  in  binding  buffer  containing 
0.1%  bovine  serum  albumin  in  the  presence  of 
horseradish peroxidase (Sigma). The concentration 
of horseradish peroxidase was 0.1 µg/ml for cow 
CD23 assays and 25 µg/ml for mouse CD23 assays. 
After incubation for 2 h at 4 ºC, wells were washed 
5  times  with  binding  buffer  and  incubated  with 
3,3',5,5'-tetramethyl benzidine peroxidase substrate 
(BioLegend). After color development for 5-30 min 
at room temperature, the reactions were stopped by 
addition of an equal volume of 100 mM H2SO4 and 
the absorbance was read at 450 nm in a Victor3 
plate reader (PerkinElmer). 
Disaccharides and oligosaccharides for 
competition  assays  and  crystallization  were 
obtained from Dextra Laboratories, except that the 
Man9GlcNAc2  oligosaccharide from soybean 
agglutinin  was  isolated  as  previously  described 
(38). For determination of pH dependence, Tris in 
the binding buffer was replaced with a mixture of 
25 mM MES and 25 mM MOPS adjusted to 
appropriate pH values. 
Glycan array 
Oligosaccharide arrays immobilized on glass 
slides were from the MicroArray Core Facility of 
The Scripps Research Institute (La Jolla, CA). The 
microarrays were comprised of 600 defined glycans 
from the Consortium for Functional Glycomics 
printed on NHS-activated microarray slides using a 
contact printer in replicates of 6 as previously 
described (39). Absence of binding of uncomplexed 
streptavidin was checked on each batch as part of 
quality control with plant lectins (39). Labelled 
proteins were diluted in 150 mM NaCl, 20 mM 
Tris-Cl, pH 7.4, 2 mM CaCl2, 2 mM MgCl2, 0.05% 
Tween 20, 1% bovine serum albumin and incubated 
with the slides. Slides were washed with 150 mM 
NaCl, 20 mM Tris-Cl, pH 7.4, 2 mM CaCl2, 2 mM 
MgCl2  and scanned with an InnoScan 1100AL 
scanner    with  data  processed  using Mapix  8.2.5 
software (Innopsys, Chicago, IL). For each set of 
six  replicate  spots,  the  mean  and  standard 
deviations were calculated after the highest and 
lowest values were excluded. Glycan microarray 
analyses  were  carried  out  according  to  the 
guidelines  proposed  by  the  MIRAGE  initiative 
(40). 
 
Glycoprotein blotting experiments 
Glycoprotein resolved by SDS-polyacrylamide 
gel electrophoresis were blotted onto nitrocellulose 
membranes,  which  were  blocked  for  30  min  at 
room temperature with 5% bovine serum albumin 
in binding buffer as defined above for solid phase 
binding assays. CRD-streptavidin-alkaline 
phosphatase complexes were added to a final 
concentration of 0.1-0.2 μg/ml and incubated for 60 
min at room temperature. Following four 5-min 
washes with binding buffer, blots were developed 
with nitroblue tetrazolium/5-bromo-4-chloro-3- 
indolyl phosphate phosphatase substrate (Merck). 
 
Crystallization, data collection, and structure 
determination 
Crystals  of  CD23  complexed  with  α-methyl 
mannoside were grown by hanging drop vapor 
diffusion at 16.5 °C using a mixture of 0.9:0.9 μl of 
protein:reservoir solution in each drop, with the 
protein solution comprising 4.2 mg/ml protein, 5 
mM CaCl2, 10 mM Tris-Cl, pH 8.0, 25 mM NaCl, 
and 50 mM α-methyl mannoside. The reservoir 
solution contained 16% polyethylene glycol 4K, 0.1 





solution containing 30% polyethylene glycol 4K, 
0.1 MES, pH 5.5, 25 mM NaCl, 5 mM CaCl2  and 
50 mM α-methyl mannoside, before being frozen in 
liquid  nitrogen  for  data  collection.  Crystals  of 
CD23 with GlcNAcβ1-2Man were grown at 22 °C 
using a mixture of 0.9:1.8 μl of protein:reservoir 
solution, with the protein solution containing 5 
mg/ml protein, 5 mM CaCl2, 10 mM Tris-Cl, pH 
8.0, 25 mM NaCl, and 50 mM GlcNAcβ1-2Man. 
The reservoir solution contained 24% polyethylene 
glycol 8K, 0.1 HEPES pH 7.0. Crystals were frozen 
directly from the drop in liquid nitrogen for data 
collection. Crystals of CD23 complexed with 
GlcNAc2Man3  were grown at 16.5 °C using a 
mixture of 0.9:0.9 μl of protein:reservoir solution. 
The protein solution comprised 5 mg/ml protein, 5 
mM CaCl2, 10 mM Tris-Cl, pH 8.0, 25 mM NaCl, 
and 10 mM GlcNAc2Man3. The reservoir solution 
contained 22% polyethylene glycol 8K, 0.1 M 
HEPES pH 7.0. Crystals were frozen directly from 
the drop in liquid nitrogen for data collection. 
Diffraction data were measured at 100 K on 
Beamline 12-2 at the Stanford Synchrotron 
Radiation Laboratory. Diffraction data were 
integrated  with XDS and scaled with AIMLESS 
(41) to a maximum resolution of 1.0 Å for the 
complex with α-methyl mannoside, 1.2 Å for the 
complex with GlcNAcβ1-2Man, and 2.7 Å for the 
complex with GlcNAc2Man3. Data statistics are 
summarized in Table 1. 
The  structure  of  CD23  complexed  with  α- 
methyl mannoside was solved by molecular 
replacement with Phaser (42). The model used for 
molecular replacement was prepared from the 
coordinates of the human CD23 structure, Protein 
Data Bank entry 2H2T, using the protein chain and 
the Ca2+ ion. The molecular replacement solution 
confirmed that the space group was P212121, with 
one CD23 molecule in the asymmetric unit. 
Difference Fourier maps revealed that in addition to 
the primary Ca2+, there is an additional Ca2+ ion and 
that  the  α-methyl  mannoside  is  bound  to  the 
primary Ca2+ ion in two orientations. 
The crystals of CD23 complexed with 
GlcNAcβ1-2Man had the same symmetry and unit 
cell parameters as the complex with α-methyl 
mannoside,  so the structure was solved by rigid 
body refinement starting with the CRD from the 
model of the α-methyl mannoside complex, with 
two Ca2+  ions and with one water molecule bound 
to the secondary Ca2+  ion. The carbohydrate and 
other  water  molecules  were  removed  from  the 
initial  model.  The  same  Rfree    reflections  were 
chosen for both complexes. 
The structure of CD23 complexed with 
GlcNAc2Man3   was  solved  by  molecular 
replacement using the same initial model used for 
the  CD23  GlcNAcβ1-2Man  complex.  The 
molecular replacement solution confirmed that the 
space group was P3121, with one CD23 molecule in 
the asymmetric unit. Difference Fourier maps 
revealed that the GlcNAc2Man3 oligosaccharide 
crosslinks two symmetry-related CD23 molecules. 
The sugar, which can be described as a central Man 
residue with two GlcNAcβ1-2Man moieties linked 
to the 3- and 6-OH groups, sits on a two-fold axis. 
The two GlcNAcβ1-2Man groups of the 
carbohydrate superimpose closely on one another 
and are well defined in the electron density maps. 
The mannose moiety of each GlcNAcβ1-2Man 
branch bind the primary Ca2+  in one unit cell and 
the primary Ca2+  in a symmetry-related unit cell. 
The central mannose residue of the pentasaccharide 
has two conformations, each at 50% occupancy, 
with the GlcNAcβ1-2Man moiety from either the 
α1-3 or α1-6 linked branch bound to the protein. 
Since the carbohydrate is on a two-fold axis, it is 
defined with 0.5 occupancy and the non-bonded 
interactions for the carbohydrate with symmetry 
related carbohydrate were turned off. 
Model building and refinement were performed 
with Coot and PHENIX (43,44). Refinement 
included individual positional, and isotropic 
temperature  factor  refinement  of  the  sugar  and 
water molecules and the protein of the GlcNAcβ1- 
2Man and GlcNAc2Man3  complex. Anisotropic 
temperature factor refinement was used for the 
protein in the high-resolution α-methyl mannoside 
complex. For the α-methyl mannoside complex, 
riding hydrogen atoms were added to the protein 
and the carbohydrate. TLS refinement, secondary 
structure restraints and reference model restraints 
were used in the refinement of the GlcNAc2Man3 




Peripheral blood mononuclear cells were isolated 
by density gradient centrifugation (Lymphoprep, 
STEMCELL technologies, Cambridge, UK), using 
whole blood from cattle sampled under home office 





nitrogen. Prior to staining, the cells were defrosted 
and rested for 2 hours at 37°C with 5% CO2   in 
RPMI 1640 medium (Gibco, Thermo Fisher 
Scientific, Hemel Hempstead, UK) supplemented 
with 10% FBS (Sigma-Aldrich, Poole, UK). The 
following antibodies were used to stain the cells in 
this study: CD23 (9p25, IgG1, Dendritics, Lyon, 
France), CD21 conjugates with R-phycoerythrin 
(CC51, IgG2b, Bio-Rad Laboratories, Watford, 
UK),  IgG1  isotype  control  (15H6, 
SouthernBiotech, Birmingham, USA), IgG2b 
conjugates with R-phycoerythrin  isotype control 
(Bio-Rad Laboratories), rabbit F(ab’)2 anti-mouse 
IgG  conjugates  with  fluorescein  isothiocyanate 
(Bio-Rad  Laboratories).  Staining  with  each 
antibody was performed in phosphate-buffered 
saline containing 2% bovine serum albumin for 30 
min at 4°C. Flow cytometry data were acquired on 
a FACSCalibur  (BD  Biosciences,  Reading,  UK) 
and analysis was performed using FlowJo V10 
(FlowJo, LLC, Ashland, USA). 
 
Sequence identification and alignment 
CD23 sequences were identified in the National 
Center for Biotechnology Information database and 
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Crystallographic data statistics 
 






Symmetry P212121 P212121 P3121 
Wavelength (Å) 0.81566 0.97946 0.97946 
 







Resolution Å (last shell) 1.00 (1.02-1.00) 1.20 (1.22-1.20) 2.7 (2.83) 
Rsym (last shell)
a
 3.3 (11.9) 6.6 (15.2) 10.5 (34.4) 
Mn(I) half-set correlation CC(1/2) 0.998 (0.990) 0.993 (0.977) 0.996 (0.985) 
Mean((I)/(I)) (last shell) 33.5 (12.3) 16.9 (9.5) 13.7 (3.1) 
% completeness (last shell) 99.7 (98.5) 99.7 (98.9) 99.5 (96.9) 
Number of unique reflections 67049 37766 4156 
Average multiplicity (last shell) 6.4 (5.8) 6.3 (5.6) 16.9 (12.9) 
 
aRsym =  100x∑h∑I  (| Ii(h) - <I(h)> |) / ∑h∑i Ii(h) where Ii(h) = observed intensity, and <I(h)> = mean intensity 














Number of reflections used for 
refinement 
63632   [[[R-89]]] 35787    [[[R-23]]] 3926 [[[R-19]]] 
 
Reflections marked for Rfree 3350 1890 183 
Rfree
a
 12.8 16.5 25.1 
Rcryst
a
 11.4 15.1 19.9 
Average B factor  (Å2) 10.2 10.1 85.3 
Bond length rmsd (Å) 0.006 0.006 0.012 
Angle rmsd (˚) 1.04 0.92 1.46 
Ramachandran plot: (% in 








PDB Codes 6PWS 6PWR 6PWT 
 
aR and Rfree  = 100x∑h  |Fo(h)-Fc(h)| / ∑hFo(h), where Fo(h) = observed structure factor amplitude and Fc(h) = 
calculated structure factor amplitude for the working and test sets, respectively. 







Figure 1. Expression of cow CD23. A, Domain organization of CD23. B, Sequence alignment of CD23 
from human, mouse, and cow. The transmembrane region is highlighted in violet and the a and d positions 
of the heptad repeats in the neck are highlighted in orange. Conserved cysteine residues, linked by disulfide 
bonds, are shaded yellow. Positions of residues that commonly interact with Ca2+ are indicated in green for 
the conserved sugar-binding site and in pink for an accessory site found in some C-type CRDs. Residue 
numbers correspond to the cow protein based on sequence XP_002688905.2 from the National Center for 
Biotechnology Information. C/D, SDS-polyacrylamide gel electrophoresis of fractions eluted from a 
mannose-Sepharose column with EDTA for the CRD fragment alone and with an appended biotin tag. Gels 
were stained with Coomassie blue. 
 
Figure 2. Characterization of cow CD23 binding to sugars in solid phase binding assay. A, binding 
competition assays in which immobilized CRD was probed with horseradish peroxidase, as reporter ligand, 
at  concentrations  well  below  saturation  binding.  Under  these  conditions,  the  relative  KI   values  for 
competing monosaccharide and oligosaccharide ligands closely approximate KD values. The solid bars 
represent the KI values for various sugars relative to the KI for mannose. Error bars represent the standard 
deviations for three or more assays for each sugar. Absolute KI values are indicated at the top of each bar. 
B, Comparison of binding of α-methyl mannoside and Man9GlcNAc2  oligosaccharide. An example of a 
competition assay is shown. The average ratio of the affinities for five assays was 240 ± 50. C, pH 
dependence of binding was determined using the same solid phase assay format. 
 
Figure 3. Glycan array analysis of cow CD23. A, a glycan array comprising oligosaccharides from the 
Consortium for Functional Glycomics was probed with a tetravalent complex of biotin-tagged CRD with 
fluorescently labeled streptavidin. Results are color-coded based on the presence of reducing-end 
GlcNAcβ1-2Man epitopes (blue bars), GlcNAcβ1-2Man with galactose linked 1-3 to the GlcNAc residue 
(cyan bars), oligomannose structures (green bars), or Fucα1-2Gal disaccharide (red bars). Complete results 
for all oligosaccharides on the array are given in Table S1. B, Structures of oligosaccharide ligands that 
show the strongest signals on the glycan array. 
 
Figure 4. Probing of glycoproteins with cow CD23. Glycoproteins were separated by SDS- 
polyacrylamide gel electrophoresis. In each panel, Coomassie blue-stained gel is shown on the left and blot 
probed with CRD-avidin-alkaline phosphatase complex is shown on the right. A, serum glycoproteins. B, 
natural glycoproteins and versions that have been modified to expose novel reducing-end sugars. 
 
Figure 5. Structure of the CRD from cow CD23. A, Overall structure of the CRD bound to GlcNAcβ1- 
2Man. Protein in cartoon representation is colored from blue (N terminus) to red (C terminus). Disulfide 
bonds are shown in yellow. The disaccharide ligand is shown in stick representation, with carbon atoms in 
gray, oxygen atoms in red, and Ca2+ in orange. B, Superposition of ligand-binding sites in the three crystal 
structures, with carbon atoms shown in yellow for α-methyl mannoside, gray for GlcNAcβ1-2Man, and 
cyan for GlcNAc2Man3.  Oxygen,  nitrogen,  and Ca
2+   are as in A. C-E, Fo−Fc   electron  density  maps 
calculated by omitting the sugar residue from the model, contoured at 3.0 σ, and shown as a green mesh for 
α-methyl mannoside (C), GlcNAcβ1-2Man (D), and GlcNAc2Man3 (E). F-I, close-up views of the Ca
2+ and 
the ligand-binding sites. F. α-Methyl mannoside in the primary sugar-binding site, with OH groups 3 and 
4 of mannose ligated to the conserved Ca2+. For clarity, only one orientation of the sugar is shown. G, 
Accessory Ca2+ site, with ligands from 4 side chains as well as the backbone carbonyl group of Glu259. H, 
GlcNAcβ1-2Man in the primary sugar-binding site, ligated to the conserved Ca2+. I, Interactions of the 
GlcNAc moiety of GlcNAcβ1-2Man at the secondary binding site. Protein in cartoon representation as well 
as carbon atoms of stick representations are presented in gray, carbon atoms of the sugar are cyan for α- 





Figure 6. Comparison of cow and human CD23. A, Flexibility in loops 1 and 4 shown in superposition 
of the CRDs of cow and human CD23. The CRD from the complex of cow CD23 with α-methyl mannoside 
is shown in gray. Human CD23 without bound Ca2+ (PDB entries 2H2R and 4G96) are shown in blue and 
cyan and with Ca2+ bound is shown in red (PDB entry 2H2T). B, Superposition of the CRD of cow CD23, 
with GlcNAcβ1-2Man in red, human CD23 complexed with domains Cε3 and Cε4 of IgE in the presence 
of Ca2+  (PDB entry 4GKO) in blue, human CD23 complexed with domains Cε3 and Cε4 of IgE in the 
absence of Ca2+  (PDB entry 4EZM) in cyan, and CD23 complexed with domains Cε2 - Cε4 of IgE in the 
absence of Ca2+ (PDB entry 5LGK) in green. 
 
Figure 7. Crosslinking of two CRDs of cow CD23 complexed with a biantennary ligand. A, Individual 
terminal GlcNAcβ1-2Man disaccharides on two branches of the oligosaccharide interacting with sugar- 
binding sites in CRDs from CD23 and a symmetry-related molecule. Protein in cartoon representation in 
gray and cyan. Ca2+  is represented in orange spheres. The biantennary ligand is shown in stick 
representation, with carbon atoms in gray or cyan and oxygen atoms in red. B, Overall orientation of CRDs 
bound to the two branches of the bi-antennary glycan in the context of two receptor trimers. The two-fold 
axis relating the CRDs is perpendicular to the membrane. 
 
Figure 8. Flow cytometry to demonstrate expression of cow CD23 on B cells. Peripheral blood 
mononuclear cells were isolated from cow blood and stained with monoclonal anti-CD21 and anti-CD23 
antibodies. Gating based on forward and side scattering followed by CD21 expression was used to examine 
mature B cells. 
 
Figure 9. Expression of mouse CD23. A, SDS-polyacrylamide gel electrophoresis of fractions eluted from 
a 10-ml mannose-Sepharose column for the CRD fragment of mouse CD23 with appended biotin tag. 
Following application of renatured protein, the column was washed with 10 1-ml aliquots of buffer 
containing 25 mM Ca2+ and eluted with 15 1-ml aliquots of buffer containing 2.5 mM EDTA. Fractions 11- 
12, corresponding to material weakly bound to the column, were used for coating of assay plates and 
formation of streptavidin complexes. B, SDS-polyacrylamide gel electrophoresis of fractions eluted from a 
1-ml mannose-Sepharose column for the biotin-tagged complexed with Alexa Fluor 647-labeled 
streptavidin. The column was washed with 1 ml of buffer containing 25 mM Ca2+ and eluted with 7 aliquots 
(0.25 ml) of buffer containing 2.5 mM EDTA. Gels were stained with Coomassie blue. 
 
Figure 10. Characterization of mouse CD23 binding to monosaccharides in solid phase binding assay. 
Binding competition assays were performed with immobilized CRD probed with horseradish peroxidase. 
Error bars represent the standard deviations for three or more assays for each sugar. Absolute KI values are 
indicated at the top of each bar. 
 
Figure 11. Probing of glycoproteins with mouse CD23. Glycoproteins were separated by SDS- 
polyacrylamide gel electrophoresis. In each panel, Coomassie blue-stained gel is shown on the left and blot 
probed with CRD-avidin-alkaline phosphatase complex is shown on the right. A, natural glycoproteins. B, 
glycoproteins modified to expose novel reducing-end sugars. 
 
Figure 12. Evolution of Ca2+- and sugar-binding sites in CD23. A, Monophyletic arrangement of groups 
of primates in which one or more of the residues needed to form functional Ca2+- and sugar-binding sites 
are mutated. For each genus, a green check mark indicates conservation of the sites compared to cow CD23 
while an x indicates that there are changes in one or more residues in these sites. B, Sequence alignment 
showing details of amino acid changes in representative species within each genus. Sequences for all of the 
available mammalian CD23 orthologues are given in Figure S1. Residues that ligate the conserved Ca2+ 





Figure 13. Multiple binding interfaces of CD23. Two views of the cow CD23 structure highlighting 
residues that interacts with various ligands. Red indicates residues that bind to sugars. Blue corresponds to 
the portions of human CD23 that bind to IgE. Green correspond to the integrin-binding regions of human 
CD23. The binding site for CD21 in human CD23 maps to a C-terminal extension. 
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Humans   X 
Chimpanzees   X 
Gorillas X 
Orangutans  X 
Gibbons  X 
Black snub-nosed monkey X 
Colobus X 
Green monkey X 
Rhesus monkey X 
Gelada X 
Pig-tailed macaque X 
Drill X 








Coquerel's sifaka   

























B Human                                 WIGLRNLDLKGEFIWVDGSHVDYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFC 
Chimpanzee                         WIGLRNLDLKGEFIWVDGSHVDYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFC 
Western gorilla                     WIGLRNLDLKGEFIWVDGSHVDYSNWAPGEPTSRSQGKDCVMMRGSGRWNDAFC 
Sumatran orangutan            WIGLRNLDLKGEFIWVDGSHVDYSNWAPGEPTSRSQGEDCVMMRGSGHWHDAFC 
Gibbon                                 WIGLRNLDLKGEFVWVDGSHVDYSNWAPGEPTSRSQGEDCVMMRGSGHWNDAFC 
 
Black snub-nosed monkey  WIGLRNLNLKGEFIWVDGSPVDYSNWAPGEPTSQSQGKDCVMMRGSSHWNNAFC 
Ugandan red colobus          WIGLRNLNLKGEFIWVDGSPVDYSNWAPGEPTSQSQGKDCVMMRGSSHWNNAFC 
Angolan colobus                  WIGLRNLNLKGEFIWVDGSPVDYSNWAPGEPTSQSQGKDCVMMRGSSHWNNAFC 
Green monkey                     WIGLRNLNLKGEFIWVDGSPVDYSNWAPGEPTNQSHGKDCVMMRGSGHWNNAFC 
Rhesus monkey                   WIGLRNLNLKGEFIWVDGSPVDYSNWAPGEPASQSHGKDCVMMRGSSHWNNAFC 
Gelada                                 WIGLRNLNLKGEFIWVDGSPVDYSNWAPGEPASQSHGKDCVMMRGSSHWNNAFC 
Pig-tailed macaque              WIGLRNLNLKGEFIWVDGSPVDYSNWAPGEPASQSHGKDCVMMRGSSHWNNAFC 
Drill                                       WIGLRNLNLKGEFIWVDGSPVDYSNWAPGEPASQSHGKDCVMMRGSSHWNNAFC 
Sooty mangabey                  WIGLRNLNLKGEFIWVDGSPVDYSNWAPGEPASQSHGKDCVMMRGSSHWNNAFC 
 
Capuchin               WIGLRNLDLKGEFIWMDGTPVDYSNWAPEEPTNRNQGEDCVMMRGSGDWNDIYC 
Marmoset                             WIGLRNLDLKGEFIWMDGTPVDYSNWAPEEPTNRNQGEDCVMMRGSGDWNDIYC 
Bolivian squirrel monkey      WIGLRNLDLKGEFIWMDGTPVDYSNWAPEEPTNRNQGEDCVMMRGSGDWNDIYC 
 
Philippine tarsier                  WIGLRDLDVEGEFIWMDGSPVDYSNWLPGEPNNHGQGEDCVMMQGSGHWNDILC 
Coquerel's sifaka                 WIGLQDLDREGQFTWMDGSPMGYSNWYPGEPNNQGQGEDCVMMRGSGQWNDAAC 
Grey mouse lemur               WIGLQDLDREGQFTWMDGTPMDYSNWSPGEPNNQAQGEDCVMMRGSGQWNDAAC 
Bushbaby                             WIGLQDLDREGQFTWMDGSPVSYSNWYPGEPNNQDQGENCVMMRGSGQWNDAAC 
 
House mouse                       WIGLQDLNMEGEFVWSDGSPVGYSNWNPGEPNNGGQGEDCVMMRGSGQWNDAFC 
ow  WIGLRDLDIEGEFIWMDNQPLDYSNWQPGEPNDAGQGENCVMMLGSGKWNDAFC 
. . . . . 
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